Limited penetration of posaconazole into cerebrospinal fluid in an allogeneic stem cell recipient with invasive pulmonary aspergillosis

Bone Marrow Transplantation

Volumn 44, Issue 4, 2009, Pages 269-270

  Reinwald, M ^a   Uharek, L ^a   Lampe, D ^b   Grobosch, T ^b   Thiel, E ^a   Schwartz, S ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Institut für Toxikologie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; CYTARABINE; FLUDARABINE; MELPHALAN; POSACONAZOLE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG PENETRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEUKEMIA RELAPSE; LEUKEMIC MENINGITIS; LOADING DRUG DOSE; LUNG ASPERGILLOSIS; MALE; MASS SPECTROMETRY; MONOTHERAPY; PRIORITY JOURNAL; RECIPIENT; REDUCED INTENSITY CONDITIONING; REPEATED DRUG DOSE;

ACUTE DISEASE; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CENTRAL NERVOUS SYSTEM FUNGAL INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID; LUNG DISEASES, FUNGAL; MALE; TRIAZOLES; YOUNG ADULT;

EID: 69749123367     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.17     Document Type: Article

References (10)

1. Jantunen E, Volin L, Salonen O, Piilonen A, Parkkali T, Anttila VJ et al. Central nervous system aspergillosis in allogeneic stem cell transplant recipients. Bone Marrow Transplant 2003; 31: 191-196.
2. Schwartz S, Thiel E. Update on the treatment of cerebral aspergillosis. Ann Hematol 2004; 83(Suppl 1) S42-S44.
3. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003; 37: 728-732.
4. Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Cornely OA et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005; 106: 2641-2645.
5. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-347.
6. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases. Clin Infect Dis 2006; 42: e61-e65.
7. Perfect JR, Cox GM, Dodge RK, Schell WA. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother 1996; 40: 1910-1913.
8. Ruping MJ, Albermann N, Ebinger F, Burckhardt I, Beisel C, Muller C et al. Posaconazole concentrations in the central nervous system. J Antimicrob Chemother 2008; 62: 1468-1470.
9. de Boer AG, Gaillard PJ. Drug targeting to the brain. Annu Rev Pharmacol Toxicol 2007; 47: 323-355.
10. Miyama T, Takanaga H, Matsuo H, Yamano K, Yamamoto K, Iga T et al. P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. Antimicrob Agents Chemother 1998; 42: 1738-1744.